首页> 美国卫生研究院文献>Journal of Lipid Research >Inhibition of plasminogen activation by apo(a): role of carboxyl-terminal lysines and identification of inhibitory domains in apo(a)
【2h】

Inhibition of plasminogen activation by apo(a): role of carboxyl-terminal lysines and identification of inhibitory domains in apo(a)

机译:apo(a)对纤溶酶原激活的抑制作用:羧基末端赖氨酸的作用和apo(a)中抑制域的鉴定

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Apo(a), the distinguishing protein component of lipoprotein(a) [Lp(a)], exhibits sequence similarity to plasminogen and can inhibit binding of plasminogen to cell surfaces. Plasmin generated on the surface of vascular cells plays a role in cell migration and proliferation, two of the fibroproliferative inflammatory events that underlie atherosclerosis. The ability of apo(a) to inhibit pericellular plasminogen activation on vascular cells was therefore evaluated. Two isoforms of apo(a), 12K and 17K, were found to significantly decrease tissue-type plasminogen activator-mediated plasminogen activation on human umbilical vein endothelial cells (HUVECs) and THP-1 monocytes and macrophages. Lp(a) purified from human plasma decreased plasminogen activation on THP-1 monocytes and HUVECs but not on THP-1 macrophages. Removal of kringle V or the strong lysine binding site in kringle IV10 completely abolished the inhibitory effect of apo(a). Treatment with carboxypeptidase B to assess the roles of carboxyl-terminal lysines in cellular receptors leads in most cases to decreases in plasminogen activation as well as plasminogen and apo(a) binding; however, inhibition of plasminogen activation by apo(a) was unaffected. Our findings directly demonstrate that apo(a) inhibits pericellular plasminogen activation in all three cell types, although binding of apo(a) to cell-surface receptors containing carboxyl-terminal lysines does not appear to play a major role in the inhibition mechanism.
机译:Apo(a)是脂蛋白(a)[Lp(a)]的区别蛋白成分,与纤溶酶原具有序列相似性,并且可以抑制纤溶酶原与细胞表面的结合。血管细胞表面产生的纤溶酶在细胞迁移和增殖中起着重要作用,这是动脉粥样硬化的两个纤维增生性炎症事件。因此评估了载脂蛋白(a)抑制血管细胞中纤溶酶原激活的能力。发现apo(a)的两种亚型,即12K和17K,可显着降低人脐静脉内皮细胞(HUVEC)和THP-1单核细胞和巨噬细胞上的组织型纤溶酶原激活物介导的纤溶酶原激活。从人血浆中纯化的Lp(a)会降低THP-1单核细胞和HUVEC上的纤溶酶原激活,但不会降低THP-1巨噬细胞上的纤溶酶原激活。去除kringle V或kringle IV10中强赖氨酸结合位点完全消除了apo(a)的抑制作用。在大多数情况下,用羧肽酶B处理以评估羧基末端赖氨酸在细胞受体中的作用会导致纤溶酶原激活以及纤溶酶原和apo(a)结合的减少;但是,apo(a)对纤溶酶原激活的抑制作用不受影响。我们的发现直接表明,载脂蛋白(a)在所有三种细胞类型中均抑制细胞周围纤溶酶原的激活,尽管载脂蛋白(a)与含有羧基末端赖氨酸的细胞表面受体的结合在抑制机制中似乎并未发挥主要作用。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号